The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy
Vascular Diseases, Peripheral, Venous Insufficiency of Leg, Varicose Veins of Lower Limb
About this trial
This is an interventional treatment trial for Vascular Diseases, Peripheral focused on measuring Radiofrequency ablation combined with sclerotherapy, varicose veins, Sulodexide
Eligibility Criteria
Inclusion Criteria: Age >18 years and <80 years, and able to understand the requirements of the study and provide informed consent and accept the exams and follow-up. C2 - C5 varicose veins / CVI Symptomatic primary GSV, SSV, or AASV incompetence, with reflux >0.5 seconds on color duplex, eligible for patients undergoing radiofrequency ablation plus sclerotherapy BMI<35 The skin color is within the normal range, and no obvious skin color unevenness or skin diseases affect the observed indicators. Exclusion Criteria: Acute superficial or deep vein thrombosis History of asthma and stroke There are skin diseases, scars, infections, and other conditions in the surgical area that affect the observation indicators Pregnancy Serious damage to liver and kidney function Severe obesity (BMI>35) and severe edema of the lower extremities Others are not eligible for intravenous radiofrequency ablation combined with sclerotherapy
Sites / Locations
- Hospital of Chengdu University of Traditional Chinese Medicine
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Taking sulodexide
Not taking drug
Sixty patients with varicose veins who received radiofrequency ablation combined with sclerotherapy were given Sulodexide softgels 250LSU twice a day for two months after surgery。
Sixty patients with varicose veins of the lower extremities who received radiofrequency ablation combined with sclerotherapy were selected and did not take sulodexide after surgery.